Ropes & Gray represented SK Biopharmaceuticals on the transaction. SK Biopharmaceuticals announced it has entered into an global licensing agreement with radiotherapy company Full-Life Technologies (“Full-Life”)...
You must be a Standard 1 Year member to access this content.
Skadden is advising Edwards Lifesciences, while Ropes & Gray is providing legal counsel to BD on the deal. Edwards Lifesciences has entered into a definitive agreement...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised G1 Therapeutics, Inc. on the transaction. G1 Therapeutics (Nasdaq: GTHX) announced it has entered into a global license agreement, excluding the Asia Pacific region, with...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised ImmunoGen, while Walder Wyss advised the funds managed by Pharmakon Advisors. ImmunoGen, Inc. (Nasdaq: IMGN) announced it has entered into a term loan...
You must be a Standard 1 Year member to access this content.
Ropes & Gray represented a consortium led by Silversmith Capital Partners and Health Velocity Capital on the deal. A consortium led by Silversmith Capital Partners and...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised National Resilience on the deal. National Resilience, Inc., a biopharmaceutical manufacturing specialist, closed a strategic alliance with bluebird bio, Inc., to accelerate...
You must be a Standard 1 Year member to access this content.
